Ensign Peak Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Ensign Peak Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Sell	262,896 -12,215	-4%	-$72.3K	﹤0.01%	763
2026 Q1	$1.23M	Hold	275,111	–	–	﹤0.01%	798
2025 Q4	$1.51M	Buy	+275,111	New	+$1.34M	﹤0.01%	752
2022 Q2	–	Sell	-1,410	Closed	-$9K	–	2202
2022 Q1	$9K	Hold	1,410	–	–	﹤0.01%	2191
2021 Q4	$16K	Buy	+1,410	New	+$21.3K	﹤0.01%	2186

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ensign Peak Advisors's TSHA Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Taysha Gene Therapies (TSHA) stake by 4.4% in Q2 2026, selling an estimated $72.3K and leaving 262,896 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #763.

Ensign Peak Advisors first reported a position in TSHA in Q4 2021 and has held it in 5 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Ensign Peak Advisors held 262,896 shares of Taysha Gene Therapies worth $1.79M as of Q2 2026.
Ensign Peak Advisors sold 12,215 Taysha Gene Therapies shares in Q2 2026, an estimated $72.3K.
Taysha Gene Therapies made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #763 holding.
Ensign Peak Advisors first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 5 quarters since.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.